For two decades now, and counting, the LANDFIRE program continues to assemble the most easy-to-use, intuitive and complete clearinghouse of remote sensing data products for wildland fire managers. 

Restoration of the imperiled sagebrush biome will require tools that assist resource managers in determining which restoration practices are most effective, and when and where restoration efforts will lead to the most ecosystem recovery. New research from USGS and Colorado State University provides biome-wide insights and spatially explicit tools that can inform restoration practices. 

Geologists from the Yellowstone Volcano Observatory are often asked to estimate how likely future eruptions are at Yellowstone, but it’s no walk in the national park.

Circus of Books storefront.; Credit: Netflix/Circus Of Books (2020)

The documentary “Circus of Books”  tells the story of two book stores, one in West Hollywood and the other in Silver Lake, operated by Karen and Barry Mason, who became accidental book sellers. They also became real pillars of the LGBTQ communties. Rachel Mason is the daughter of the masons and she’s also the filmmaker. Larry talked with Rachel about “Circus of Books” when it was first released on Netflix. Today on FilmWeek, we excerpt a portion of that conversation. 

This conversation aired during FilmWeek’s Saturday broadcast. 

Guest: 

Rachel Mason, director of the Netflix documentary ‘Circus of Books’ and daughter of Circus of Books owners Karen and Barry Mason; she tweets @RachelMasonArt

This content is from Southern California Public Radio. View the original story at SCPR.org.

Shot from the film “The Boss Baby: Family Business”; Credit: Dreamworks

Larry Mantle and KPCC film critics Lael Loewenstein, Wade Major and Charles Solomon review this weekend’s new movie releases on streaming and on demand platforms.

• "The Forever Purge," in wide release

• "The Boss Baby: Family Business," in wide release & on Peacock

• "Long Story Short," at Laemmle’s Glendale; & on VOD/Digital (including Vudu, FandangoNow & Google Play)

• "The Tomorrow War," on Amazon Prime Video

• "The One And Only Dick Gregory," premieres on Showtime July 4 at 9 pm PT, available on demand on Showtime following that

• "No Sudden Move," on HBO Max

• "The Ladykillers (Originally released in 1955)," at Laemmle Theaters (Royal, Town Center 5, Playhouse 7)

• "America: The Motion Picture," on Netflix

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Lael Loewenstein, film critic for KPCC; she tweets @LAELLO

Wade Major, film critic for KPCC and CineGods.com

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Michael Ballanger of GGM Advisory Inc. shares his thoughts on the silver market and shares one copper stock he believes is a Strong Speculative Buy even though the stock is currently halted.

Source: Dr. Robert Driscoll 10/28/2024

Wedbush analysts Dr. Robert Driscoll, Dr. Ritika Das, and Sam Ravina, in a research report published on October 28, 2024, maintained their Outperform rating on Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) while raising their price target to US$15.00 from US$11.00. The report follows Monte Rosa's announcement of a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program.

The analysts highlighted the significant financial terms of the agreement, stating, "GLUE will receive an upfront payment of US$150M as well as total milestone payments of up to US$2.1B that will include US$1.5B in potential development and regulatory milestones that begin upon Ph 2 studies."

Regarding the partnership structure, the analysts noted, "Upon start of Ph 3 studies, 30% US P&L would be shared with Ph 3 development co-fund and ex-US tiered royalties. Importantly, NVS will cover the complete costs of Ph 2 studies and will obtain worldwide rights to develop, commercialize and manufacture MRT-6160 as well as other VAV MGDs."

The analysts viewed this collaboration positively, stating, "We view this favorable collaboration agreement as an additional robust validation of GLUE's QuEEN MGD platform (noting Novartis' significant efforts in the degrader space), as well as an acknowledgment of the significant potential opportunities around targeting VAV1 with a first in class degrader."

They also emphasized the strategic benefits, noting, "Furthermore, we note the likely accelerated timelines for the MRT-6160 development program overall, and significant extension of GLUE's operational cash runway, which we expect to allow advancement of its deep pipeline."

The report highlighted the ongoing Phase 1 SAD/MAD healthy subject study for MRT-6160 in autoimmune diseases, with initial data expected in 1Q:25.

Wedbush's valuation methodology is based on sales multiples. The analysts explained, "Our PT is derived from applying a 6x multiple to estimated US sales and a 15x multiple to EU royalties of MRT-2359 in 2031, discounted by 30% annually."

The analysts also outlined several risk factors, including potential clinical and regulatory failure of MRT-2359, challenges in achieving sales estimates, and possible commercial competition from current and future therapies.

In conclusion, Wedbush's increased price target to US$15 reflects growing confidence in Monte Rosa Therapeutics following the Novartis collaboration agreement. The share price at the time of the report of US$8.05 represents a potential return of approximately 86% to the analysts' target price, highlighting the significant upside potential as the company advances its development programs with its new partner.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, Monte Rosa Therapeutics Inc., October 28, 2024

Analyst Certification We, Robert Driscoll, Ritika Das and Sam Ravina, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

The Distribution of Ratings is required by FINRA rules; however, WS' stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS' stock ratings are on a relative basis. The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS' total revenues, a portion of which are generated by WS' investment banking activities. Company Specific Disclosures This information is subject to change at any time. 2. WS managed a public offering of securities for Monte Rosa Therapeutics within the last 12 months. 4. WS has received compensation for investment banking services from Monte Rosa Therapeutics within the last 12 months. 5. WS provided Monte Rosa Therapeutics with investment banking services within the last 12 months.

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: GLUE:NASDAQ, )

Source: Dr. Joseph Pantginis 11/04/2024

H.C. Wainwright & Co. analysts Dr. Joseph Pantginis, Dr. Lander Egaña Gorroño, Dr. Joshua Korsen, Dr. Matthew Keller, and Dr. Sara Nik, in a research report published on November 4, 2024, maintained their Buy rating on Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) with a price target of US$6.00. The report follows Lexicon's presentation of preclinical data for LX9851, its ACSL5 inhibitor for obesity, at ObesityWeek 2024.

The analysts highlighted key findings from the presentations, stating, "LX9851 promotes reduction of fat mass without affecting lean body mass" and "LX9851 improves and sustains GLP-1 RA-mediated weight loss, even after semaglutide discontinuation." They added that "Mechanistic studies suggest that LX9851-mediated ACSL5 inhibition activates the ileal brake."

Regarding the drug's potential, they noted, "LX9851 is a first-in-class, oral small molecule ACSL5 inhibitor designed to enhance and maintain weight loss promoted by incretin mimetics (GLP-1 receptor agonists), and offer improved treatment alternatives for obesity and related metabolic disorders."

The report also addressed recent developments with sotagliflozin, detailing the AdCom voting results and potential scenarios for FDA action. The analysts stated, "Although we anticipate favorable feedback from the agency regarding eGFR ≥60 to <90 range, our bet is that a confirmatory trial may be required to validate sota's efficacy in this subpopulation and obtain approval."

H.C. Wainwright & Co.'s valuation methodology is based on a clinical net present value (NPV) model. The analysts explained, "Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. We currently value Lexicon solely on sotagliflozin sales in the U.S. for HF (INPEFA), HCM, and LX9211 for DPNP."

They added, "We believe significant upside potential exists, based on: (1) attaining higher market penetration for HF, and HCM; and (2) adding the earlier stage assets."

In conclusion, H.C. Wainwright & Co.'s maintenance of their Buy rating and US$6 price target reflects confidence in Lexicon's pipeline potential, particularly with LX9851 and sotagliflozin. The share price at the time of the report of US$1.22 represents a potential return of approximately 392% to the analysts' target price, highlighting the significant upside potential if the company's development programs prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Lexicon Pharmaceuticals Inc., November 4, 2024

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Joseph Pantginis, Ph.D., Lander Egaña Gorroño, Ph.D., Joshua Korsen, Ph.D., Matthew Keller, Ph.D. and Sara Nik, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Lexicon Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Lexicon Pharmaceuticals, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from Lexicon Pharmaceuticals, Inc. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from Lexicon Pharmaceuticals, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Lexicon Pharmaceuticals, Inc. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: LXRX:NASDAQ, )

Lithium Ionic Corp. (LTH:TSX.V; LTHCF:OTCQX; H3N:FSE) has announced the initiation of Engineering, Procurement, and Construction Management (EPCM) services for its flagship Bandeira Lithium Project. See why the CEO Blake Hyland says that the company's momentum towards production is stronger than ever.

Famed investor and commentator Jim Rogers talks his preference for tangible assets, why he's leaning toward silver over gold, and uranium's role in the energy transition.

Famed investor and commentator Jim Rogers talks his preference for tangible assets, why he's leaning toward silver over gold, and uranium's role in the energy transition.

SURFSIDE, Fla. — Crews used explosives late Sunday night to demolish the remaining structure at Champlain Towers South in Surfside, Fla.

The heavily damaged condo building was knocked down at about 10:30 p.m. Eastern time.

The targeted blast caused the tower to fold and crumble, sending a large plume of dust and debris over a section of the beachside community. A crowd watching from a distance prayed as the building came down.

Before the structure was leveled, Miami-Dade County police urged residents who live nearby to remain indoors and shelter in place.

Miami-Dade County officials said removing the tower was an essential step so search and rescue teams could resume scouring the rubble pile for victims of the disaster.

Officials suspended recovery efforts on Saturday because of concerns about the danger posed by the unstable building.

"It will be safe to resume the search activities very shortly after the blast and that's when we'll resume it," said Miami-Dade County Mayor Daniella Levine Cava at a press conference Sunday evening.

Demolition of the tower was also accelerated because of Tropical Storm Elsa, which could hit South Florida with high winds and heavy rains as early as Monday.

Search efforts had been ongoing since the morning of June 24, when much of the 12-story condo complex suffered a "progressive collapse" and dozens of apartments were reduced to rubble in a matter of seconds.

The number of confirmed dead from the disaster remains at 24, with the number of people unaccounted for at 121.

Rep. Debbie Wasserman Schultz, D-Fla., told reporters Sunday the demolition of the remaining tower added to the sorrow for families who lived in the complex, destroying homes and possessions.

"So often demolitions of buildings are a spectacle, it's almost like a show," Schultz said. "This demolition is a tragic situation."

Local officials assured former residents and the public that everything possible had been done to rescue pets left behind in the structure.

"Folks can be comfortable we're not leaving anyone behind, including our beloved pets," Surfside Mayor Charles Burkett told reporters.

Multiple investigations are already underway into the cause of the collapse.

Documents acquired by NPR from an anonymous source show the condo association's board received warnings from an engineering firm beginning in 2018 that the structure needed extensive repairs.

A memo sent by the association to Champlain Towers South residents ahead of a May 2021 board meeting acknowledged the "desperate needs of the building."

This content is from Southern California Public Radio. View the original story at SCPR.org.

A tropical storm with 65-mile-an-hour winds is drenching Cuba, and is expected to reach Key West and the west coast of Florida within the next 48 hours.

The National Hurricane Center expects Tropical Storm Elsa to drop between 5 and 10 inches of rain on central and western Cuba, leading to significant flooding and mudslides. The storm probably will weaken somewhat as it crosses the island, but could strengthen again as it approaches Florida.

According to the Associated Press, Cuban officials evacuated 180,000 people as a precaution against the possibility of heavy flooding.

Most of those evacuated stayed at relatives' homes, others went to government shelters, and hundreds living in mountainous areas took refuge in caves prepared for emergencies. The storm had killed at least three people on other Caribbean islands before it reached Cuba

The National Weather Service says that the western coast of Florida, including Tampa Bay, can expect a storm surge that would lift water levels between two and four feet. Much of Florida could see heavy rainfall that could reach six inches in some places. The storm will then bring heavy rains to Georgia and the Carolinas later in the week.

Florida officials were worried that the storm could destabilize what was left of the condominium building that partially collapsed over a week ago. In order to avoid an uncontrolled collapse, they approved the demolition of the remaining portion of the building, which took place on Sunday night.

"The hurricane was coming, the potential for that building to fall on the pile with the victims in it was a tragic thought," Surfside Mayor Charles Burkett told NPR on Monday.

It's early in the hurricane season. The National Oceanic and Atmospheric Administration has predicted a busier-than-average Atlantic hurricane season, but it would be hard to top last year's, which set an all-time record with 30 named storms.

Tropical storms are fueled by warm water in the upper layers of the ocean, and ocean temperatures have been rising as heat is trapped by greenhouse gases.

This content is from Southern California Public Radio. View the original story at SCPR.org.

“The technology services industry, at some level, is recession proof,” Premji said at the company’s 76th annual general meeting on Tuesday. “In good times, clients spend on new initiatives and business transformation and serving customers digitally. They focus on reducing costs when times are not so good,” he said addressing a question on inflation concerns.

Through a series of ambitious initiatives and strategic investments, India is actively working to overcome barriers and create a level playing field for technology adoption. From expanding connectivity infrastructure to investing in digital literacy programs, the nation is leaving no stone unturned in its pursuit of equitable access to technology.

The final stages of the 2011 property revaluation process in Catawba County have begun with the presentation of the proposed 2011 Schedule of Values to the Board of Commissioners, and will continue into November, when property owners will receive notice of the new value of their property, and into December and early 2011 when the appeal process begins.

The Catawba County Sheriff�s Office, in conjunction with The Cognitive Connection and The Foothills Coalition, is sponsoring an Operation Pill Stoppers program that now provides fixed locations for citizens to properly dispose of their unused and unwanted medications.

A customer walks behind a sign at a Nordstrom in Coral Gables, Fla., store seeking employees in May.; Credit: Marta Lavandier/AP

Two organizations filed a lawsuit against Indiana Gov. Eric Holcomb in an attempt to block the state's push to end pandemic unemployment benefits on June 19.

Indiana Legal Services, an organization providing free legal assistance, and the Concerned Clergy of Indianapolis filed the lawsuit on behalf of five unnamed plaintiffs who are set to lose their jobless benefits. The complaint was filed Monday in Marion County Superior Court.

This lawsuit may be the first of its kind that aims to stop states from ending these benefits earlier than Congress mandated.

The unemployment insurance program "has served as a vital lifeline for thousands of Hoosiers," the complaint, reviewed by NPR, says. "By prematurely deciding t0 stop administering these federal benefits, Indiana has violated the clear mandates 0f Indiana's unemployment statute—to secure all rights and benefits available for unemployed individuals."

Indiana is one of 25 Republican-led states that decided to end jobless aid in an effort to get people to return to work. Indiana and seven other states are set to end expanded unemployment benefits as soon as this weekend. This is despite Congress's authorization for extra payments until early September.

Those benefits include the extra $300 a week in federal aid and the special pandemic program for gig workers that allows them to receive jobless benefits. Ordinarily, independent contractors wouldn't be eligible.

Plaintiffs, as well as many other Indiana residents, rely entirely on the unemployment benefits to pay for food and rent and to care for their families, the complaint alleges.

Attorneys in this case are requesting the judge approve a preliminary injunction that would allow people to receive their benefits while the case continues.

Holcomb says it's time to get back to work

Holcomb told The Indianapolis Star that people no longer need unemployment benefits as the state has a plethora of jobs open.

"Eliminating these pandemic programs will not be a silver bullet for employers to find employees, but we currently have about 116,000 available jobs in the state that need filled now," he said.

According to the governor's office, Indiana's unemployment rate has recovered to 3.9% after climbing to 17% at the height of the pandemic.

The lawsuit challenges Holcomb's assertion.

Each of the five plaintiffs say they are unable to return to work due to lingering injuries or disability, health conditions that put them at risk for COVID-19 exposure, dependent children at home and no childcare available, or no positions that are available in their career field.

Workers of color feel the loss of unemployment the most

The National Employment Law Project says ending these jobless benefits early threatens the livelihoods of workers of color the most.

Millions of Americans still heavily rely on jobless aid as the country slowly reopens from pandemic-induced lockdowns, according to the organization.

As of May 22, more than 15.3 million people still needed some form of unemployment benefit—nearly twice the number who received payments when the aid programs began in late March 2020, NELP said.

According to its analysis, over 46% of unemployment insurance recipients in the states ending the programs early are people of color.

"The brunt of the impact will be felt by Black, Latinx, Indigenous, and other people of color," NELP says.

This content is from Southern California Public Radio. View the original story at SCPR.org.

To improve and ensure the efficacy of restoration efforts in the Gulf of Mexico following Deepwater Horizon – the largest oil spill in U.S. history – a new report from the National Academies of Sciences, Engineering, and Medicine recommends a set of best practices for monitoring and evaluating ecological restoration activities.

To ensure the Comprehensive Everglades Restoration Plan (CERP) is responsive to changing environmental conditions like climate change and sea-level rise, as well as to changes in water management, a new report by the National Academies of Sciences, Engineering, and Medicine calls for a re-examination of the program’s original restoration goals and recommends a forward-looking, systemwide analysis of Everglades restoration outcomes across a range of scenarios.

The U.S. Department of the Interior’s Bureau of Safety and Environmental Enforcement has ordered the National Academies of Sciences, Engineering, and Medicine to suspend all work on a study to review and update the bureau’s offshore oil and gas operations inspection program to enhance safety.

A new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine takes a comprehensive look at evidence on the human health effects of e-cigarettes.

The Gulf Research Program (GRP) of the National Academies of Sciences, Engineering, and Medicine today announced grant awards for seven new projects totaling $5.3 million.

As new evidence about climate change and sea-level rise in South Florida continues to emerge, agencies responsible for the restoration of the Everglades should conduct a mid course assessment that rigorously analyzes scenarios of future change to the region’s ecosystem in its planning, says a new congressionally mandated report by the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine offers guidance to the U.S. Environmental Protection Agency to inform the next revision of a permit program that requires industries to manage stormwater to minimize discharges of pollutants to the environment.

Two Gulf Research Program fellows reflect on their time in Mississippi after being placed with NOAA’s RESTORE Science Program. The Science Policy Fellowship helped them bridge research and action. With ideas, passion, and depth of knowledge in science and research, the fellows worked to share their backgrounds to better inform policy.

Most U.S. colleges and universities are struggling to adjust to the COVID-19 pandemic, but Historically Black Colleges and Universities — known as HBCUs — are facing their own unique challenges.

This summer, the Gulf Research Program (GRP) of the National Academies of Sciences, Engineering, and Medicine started work on a new study that will assess how climate disasters, oil spills, and long-term environmental changes such as sea level rise are affecting environmental restoration projects in the Gulf of Mexico. The study will help fulfill one of GRP’s top goals — monitoring progress and documenting how the Gulf is changing over time.

In the wake of this year’s record-breaking wildfire and hurricane season, efforts are ramping up to rebuild communities and natural ecosystems in places devastated by fire and storms. Restoring natural ecosystems requires replacing the trees, grasses, flowers, herbs, shrubs, and other plants that have evolved and occur naturally in a particular region.

As the Comprehensive Everglades Restoration Plan (CERP) pivots from planning to operations, a strong organizational foundation for science will be essential to inform management and future actions for the ecosystem, which remains vulnerable to continued degradation, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Urban freeways and transit infrastructure projects — often paid for in large part by federal transportation funds — have disproportionately displaced and isolated people living in minority neighborhoods, tearing at the fabric of vibrant communities and compounding issues of equity and access to jobs and essential services.

Social distancing, disrupted routines, and a lost sense of security and safety have made some kids and teens vulnerable to stress, anxiety, and depression during the pandemic. A new set of tools from the National Academies helps kids and adults build skills to cope with stress.

The presidents of the U.S. National Academies said in a statement that the 26th United Nations Climate Change Conference of the Parties (COP26) presents a historic global opportunity to agree on emissions reduction targets to avoid the most intolerable impacts of climate change.

Assessing the success of ecological restoration efforts since the Deepwater Horizon platform explosion and oil spill in 2010 will require continued improvements in data analysis and coordination across the Gulf of Mexico region.

The Action Collaborative on Preventing Sexual Harassment in Higher Education today released three new individually authored publications to serve as resources for higher education institutions as they work to prevent sexual harassment and mitigate the damage it causes.

This description of practice summarizes the development and implementation of a policy by the University of Wisconsin (UW) System to prevent “passing the harasser,” a term that denotes a known harasser transitioning from one institution to another without (1) the new employer’s knowledge of previous violations of sexual harassment policy or ongoing investigations of such violations, and/or (2) facing disciplinary action.

The description of practice below summarizes the development and implementation of a policy by the University of California, Davis (UC Davis) to prevent “passing the harasser,” a term that denotes a known harasser transitioning from one institution to another without (1) the new employer’s knowledge of previous violations of sexual harassment policy or ongoing investigations of such violations, and/or (2) facing disciplinary action.

Testing for exposure to PFAS — chemicals used in a broad range of consumer products for decades — should be offered to patients who are likely to have a history of elevated exposure. A new report provides advice to the CDC on how clinicians can interpret test results and deliver follow-up care.

Hurricane Ian has caused catastrophic damage to life, property, and infrastructure across Florida, and it is headed toward Georgia and the Carolinas. The National Academies have many resources aimed at better understanding hurricanes, how climate change may be affecting their intensity and frequency, and how communities can become more resilient to extreme events.

Congress should take action to facilitate the participation of all land-grant colleges and universities in multistate research projects, says a new report. Funding disparities have prevented many historically Black and tribal colleges and universities from fully collaborating with other land-grant institutions.

To reduce racial disparities in the U.S. criminal justice system, policymakers at all levels should explore ways to decrease police stops and searches, jail detention, prison admission, and long sentences through coordinated policy reforms.

The insufficient supply of seeds from native plants is a major barrier to ecological restoration and other revegetation projects across the U.S., especially as climate change increases the possibility of extreme weather events that can damage natural areas.

As AI gets closer to the ability to cause physical harm and impact the real world, “it’s complicated” is no longer a satisfying response

Ticketmaster seems to have experienced a data breach, with the ShinyHunters hacker group claiming to have exfiltrated 560 million customer data

As health data continues to be a prized target for hackers, here's how to minimize the fallout from a breach impacting your own health records

A study of a sophisticated Chinese browser injector that leaves more doors open!

In the second quarter ending September of the ongoing fiscal year 2025, LTIMindtree closed several multi-year projects including a $200 million-plus deal from a US-based manufacturer. The total order intake for the three-month period was flat year-on-year at $1.3 billion, down 7% from previous quarter.

After Musk acquired Twitter in October, the social media firm faced months of chaos, including layoffs of thousands of employees, criticism over lax content moderation, and an exodus of many advertisers who did not want their ads appearing next to inappropriate content.

For decades, scientists have tried to harness the unique properties of carbon nanotubes to create high-performance electronics that are faster or consume less power -- resulting in longer battery life, faster wireless communication and faster processing speeds for devices like smartphones and laptops.

read more

97 per cent of Fortune 500 companies have been hacked. A quarter of companies have had a serious breach in the last year.